{"id":389132,"date":"2023-11-22T00:00:00","date_gmt":"2023-11-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2023-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2023\/"},"modified":"2026-05-03T23:22:37","modified_gmt":"2026-05-03T23:22:37","slug":"dlsfon0002-2023-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2023-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Colorectal Cancer | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also benefit from EGFR inhibitors (Merck &#038; Co. \/ Eli Lilly\u2019s Erbitux and Amgen\u2019s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Notably, additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck &#038; Co.\u2019s Keytruda and Bristol Myers Squibb\u2019s Opdivo and Yervoy) for MSI-high and\/or MMR-deficient tumors; BRAF inhibitors (Array BioPharma \/ Pfizer\u2019s Braftovi) for metastatic colorectal cancer with a BRAF V600E mutation; and HER2-targeted agents in some markets (Chugai\u2019s Perjeta and trastuzumab and Seagen\u2019s Tukysa) for HER2-positive metastatic disease. Most therapies in late-stage development are intended to treat other genomic alterations (i.e., KRAS G12C mutation) or expand the immunotherapy-based approaches for treating MSS and\/or pMMR tumors.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?<\/li>\n<li>What are interviewed experts\u2019 views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?<\/li>\n<li>What are the key drivers and constraints in the colorectal cancer therapy market, and how will they change over the forecast period?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p>SOLUTION ENHANCEMENTS<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> also features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389132","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389132\/revisions"}],"predecessor-version":[{"id":576041,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389132\/revisions\/576041"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}